Blood Serum Alpha Fetoprotein Enhancer Binding Protein, a Tumor Suppressor, Decreases in Chronic HBV Hepatitis Patients as Hepatocellular Cancer Appears
Chronic hepatitis increases the risk of hepatocellular carcinoma (HCC). To test whether circulating proteins reflect hepatic carcinogenesis, sera from patients and controls were albumin depleted, enriched for glycoproteins, digested with trypsin, and subjected to reverse phase chromatography and tan...
Main Authors: | James N. Riggins, William Corey, Alfred N. Fonteh, Michael G. Harrington |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2010-01-01
|
Series: | Disease Markers |
Online Access: | http://dx.doi.org/10.3233/DMA-2010-0692 |
Similar Items
-
Value of serum PIVKA-Ⅱ, alpha-fetoprotein, and ferritin in assisting the diagnosis of HBV-related hepatocellular carcinoma
by: WEN Jun, et al.
Published: (2017-09-01) -
Hepatocellular carcinoma in children and young patients with chronic HBV infection and the usefulness of alpha‐fetoprotein assessment
by: Hitoshi Tajiri, et al.
Published: (2016-11-01) -
Metabolomic Profiles for HBV Related Hepatocellular Carcinoma Including Alpha-Fetoproteins Positive and Negative Subtypes
by: Jianping Sun, et al.
Published: (2019-10-01) -
Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity
by: Xiaoping Wang, et al.
Published: (2018-01-01) -
Alpha-fetoprotein and immunotherapy for hepatocellular carcinoma
by: Alisa, A. A. H. I.
Published: (2012)